Navigation Links
Bortezomib shows promise in reducing GVHD and reconstituting immune system in some patients
Date:12/6/2009

rrow.

The new, Phase 1 clinical trial involved 23 patients who received bortezomib-based therapy (bortezomib, tacrolimus, and methotrexate) after reduced-intensity stem cell transplants from mismatched-unrelated donors. Three dosage levels of bortezomib were tested. In updated results on 35 bortezomib-based mismatched-unrelated patients reported at ASH, GVHD rates and extent of immune system reconstitution were compared with patients who had received sirolimus-based therapy (sirolimus, tacrolimus, and methotrexate) after transplants from matched-related donors, matched-unrelated donors, and mismatched-unrelated donors.

The results show that the bortezomib-based therapy was safe and had little toxicity. Transplanted stem cells took root, or "engrafted" reliably, and the rate of GVHD in the bortezomib-based mismatched-unrelated transplants was comparable to that in sirolimus-based matched-related transplants. Interestingly, immune cell reconstitution was significantly improved in the bortezomib-based patients in the early post-transplant period (3-6 months), compared with the sirolimus-based patients.

"Our results suggest that borezomib is a promising novel immunomodulatory agent in donor stem-cell transplantation," Koreth says. "A Phase 2 trial is now accruing patients to help determine its ultimate effectiveness."


'/>"/>

Contact: Teresa Herbert
teresa_herbert@dfci.harvard.edu
617-632-5653
Dana-Farber Cancer Institute
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Data on VELCADE(R) (Bortezomib) for Injection Based Therapies to be Presented at the International Myeloma Workshop
2. FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
3. Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients
4. Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
5. VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial
6. Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma
7. Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy
8. ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity
9. FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma
10. New drug shows promise for those with clotting disorders: McMaster researcher
11. Congress Has Allowed Most Previous Medicare Cuts to Take Effect, New Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Springs, FL (PRWEB) September 18, 2014 It ... and run, sprint or walk for healthier and happier kids. ... support and participate in the 4th Annual Miami Children’s Hospital ... Wheels. http://www.hyundaihopeonwheels.org , The 5K will ... finishing location will be outside of Coral Gables City Hall ...
(Date:9/18/2014)... Johannesburg, South Africa (PRWEB) September 18, 2014 ... organization to adopt the HABIT™ Program in ... by Indaba Health and Wellness, and distributed in South ... version of the HABIT program, which has been tailored ... , IHW HABIT™ focuses on behavior modification and chronic ...
(Date:9/18/2014)... . Two ... ,International Space Station Research Competition, with their project ,Egypt ... will see the International Space Station crew perform experiments ... proteins of the hepatitis C virus under microgravity conditions. ... Station is scheduled to lift off from Cape Canaveral ...
(Date:9/18/2014)... 18, 2014 PlatinumCode, a leading ... collection products for the healthcare industry, announced earlier ... five percent of their profits of the sale ... In making the announcement, PlatinumCode has launched various ... providing clinical and hospital labs with their popular ...
(Date:9/18/2014)... 2014 T-System Inc. today announced ... documentation system — EV™ for physicians ... assessing several best-of-breed solutions, Holyoke chose T-System’s solution ... physician productivity and reimbursement, but also its ability ... still be used to capture emergency department, (ED) ...
Breaking Medicine News(10 mins):Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 2Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 3Health News:Hepatitis C virus proteins in space 2Health News:PlatinumCode Commits to Donating Five Percent of Profits from the sale of Pink Products to Support Breast Cancer Awareness 2Health News:Holyoke Medical Center ER Improves Productivity and Reimbursement with T-System 2
... active participation in their communities has led researchers to define this ... now be considered a distinct retirement role, according to an article ... (Volume 48, Number 3). , The authors identify civic ... one day per week that directly impact the local community. ...
... 6 hours for participants in phase II trial ... gout drug called pegloticase lowered levels of uric acid ... hours in most patients. , That,s the conclusion of ... and Savient Pharmaceuticals, the company that,s developing the drug. ...
... Ill., Sept. 3 Z Trim Holdings,Inc. (Amex: ... 2, 2008, the Company,entered into private placement subscription ... of convertible notes and warrants, for an,aggregate offering ... a,"Unit" and collectively, the "Units") consists of a ...
... 28,000 ratings and comments are overwhelmingly positive, ... of,Regence members would recommend their doctor to others, ... member Web site -- myRegence.com. A,"Member Feedback" feature ... on their experiences with individual providers, including,physicians, dentists, ...
... (doi:10.1016/j.clim.2008.06.009) published in Clinical Immunology, the official ... new method enabling the detection of multiple parameters of ... specific blood cells from an individual with type 1 ... play in the development of the disease and during ...
... on earnings and productivity for healthcare professionals in the United States, ... decrease in patient loads. , ... New York, NY ... focusing on earnings and productivity for physicians in America features some ...
Cached Medicine News:Health News:Experts establish baseline for civic engagement among retirees 2Health News:New Drug Helps Relieve Gout 2Health News:Z Trim Holdings, Inc. Announces Private Placement Funding 2Health News:Z Trim Holdings, Inc. Announces Private Placement Funding 3Health News:Doctors Get High Marks as Regence Members Share Opinions Online 2Health News:Fresh Medical Industry News Reveals Earnings & Productivity Changes For Physicians 2
(Date:9/18/2014)... YORK and PLAINSBORO, N.J. ... announced today its support of the National Hemophilia ... Care , which provides support to people with ... physical and psychosocial challenges that can impede disease ... six modules, Communication With Your Provider About ...
(Date:9/18/2014)... 18, 2014 After 6 months of ... finally here - the new programme for the next Cool ... of our global Cool Chain series, has just been released! ... As the lines between supply chain, logistics, QA ... programme that is broad and yet specific, focused and yet ...
(Date:9/18/2014)... 18, 2014   Regulus Therapeutics Inc . ... leading the discovery and development of innovative medicines ... ATHENA natural history of disease study in patients ... with no approved therapy. The ATHENA study is ... function markers such as Glomerular Filtration Rate ("GFR"), ...
Breaking Medicine Technology:Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 2Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 3Europe's Biggest and Longest-Running Gathering of Life Sciences Logistics, Supply Chain & QA Professionals 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 4Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 5Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 6
... March 31, 2011 Watson Pharmaceuticals, Inc. (NYSE: ... is initiating launch activities of Nulecit™ (sodium ferric ... of GeneraMedix Inc.,s, Abbreviated New Drug Application (ANDA). ... alternative to Sanofi-Aventis, Ferrlecit ® .  In July ...
... DIEGO, March 31, 2011 OncoSec Medical Inc. (OTC BB: ... tumor cancers, announced today that it has raised more than ... to three institutional investors. OncoSec issued 1,456,000 units at a ... Each unit consisted of one share of common stock and ...
Cached Medicine Technology:Watson Announces Approval of Nulecit™, the First Generic Alternative to Ferrlecit® for the Treatment of Iron Deficiency Anemia 2Watson Announces Approval of Nulecit™, the First Generic Alternative to Ferrlecit® for the Treatment of Iron Deficiency Anemia 3Watson Announces Approval of Nulecit™, the First Generic Alternative to Ferrlecit® for the Treatment of Iron Deficiency Anemia 4OncoSec Medical Closes $1.1M Financing 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: